Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

0.5337 -0.0149 (-2.72%)
Streaming Delayed Price Updated: 11:46 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amarin Corp ADR

< Previous 1 2 3 4 5 6 Next >
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Two Upcoming Investor Events
From Amarin Corporation plc
Via GlobeNewswire
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
From Amarin Corporation plc
Via GlobeNewswire
Amarin Board of Directors Announces CEO Transition
From Amarin Corporation plc
Via GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports First Quarter 2024 Business Update and Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients 
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Results of Annual General Meeting of Shareholders
- Shareholders Approve Share Repurchase Program of up to $50 Million - 
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action 
From Amarin Corporation plc
Via GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 
From Amarin Corporation plc
Via GlobeNewswire
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Chairman & CEO Issue Letter to Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amarin Corporation plc
Via GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
From Amarin Corporation plc
Via GlobeNewswire
Amarin Reports Third Quarter 2023 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Amarin Appoints Jonathan Provoost Executive Vice President, Chief Legal & Compliance Officer
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Evaluating VASCEPA®/VAZKEPA® (icosapent ethyl) and Subgroups from the REDUCE-IT Landmark Outcomes Trial to be Presented at the American Heart Association (AHA) Scientific Sessions 2023
-- Additional Mechanistic Data on Eicosapentaenoic Acid (EPA) and Real-World Characteristics of Patients with Diabetes on IPE Also Featured at the Meeting -- 
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.